TherapeuticsMD, Inc.【TXMD】 業績推移・財務諸表

(単位:千ドル) 2Q11 3Q11 1Q12 2Q12 3Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 1Q23 2Q23 3Q23 1Q24 2Q24 3Q24 1Q25
売上高 - 2 721 819 1,036 1,537 2,080 2,294 2,863 2,830 3,751 4,186 4 4,475 4,847 5,190 5,630 4,930 4,403 5,535 4,487 3,985 4,250 4,417 4,125 3,773 3,763 3,473 5,089 3,946 6,078 23,719 15,902 12,250 10,701 19,342 22,577 19,866 23,001 25,406 18,678 19,333 28,561 20,917 416 437 -53 - - - 393
売上成長率(%) - - - - - - - - - -
売上原価 - - 336 372 306 380 463 648 - 830 892 1,068 - 1,043 1,033 1,193 - 1,108 1,130 1,237 - 659 681 700 - 633 454 699 - 762 1,248 1,444 - 2,715 4,400 3,278 - 4,687 4,132 5,282 - 4,860 4,740 3,788 - - - - - - -
売上総利益 - - 385 446 729 1,156 1,617 1,646 2,396 1,999 2,858 3,117 3 3,431 3,814 3,996 4,395 3,821 3,273 4,298 3,778 3,325 3,568 3,716 3,530 3,139 3,308 2,774 4,139 3,183 4,830 22,275 13,023 9,535 6,300 16,064 16,996 15,179 18,869 20,124 13,941 14,473 23,821 17,129 416 437 -53 - - - -
売上総利益率(%) - - 100 - - - -
研究開発費 - - 411 833 1,334 1,565 1,747 4,098 - 5,908 8,234 14,909 - 18,176 24,190 16,421 - 15,097 13,841 14,664 - 7,724 8,716 6,436 - 7,039 6,798 6,708 - 6,317 4,964 4,077 - 3,268 2,742 2,027 - 2,050 2,011 1,605 - 1,400 1,580 1,112 - - - - - - -
販売管理費 - - 2,827 3,573 3,291 4,526 5,476 4,752 - 5,029 5,537 6,043 - 6,163 6,865 7,060 - 9,678 10,619 14,721 - 16,837 14,628 12,057 - 20,757 29,466 30,354 - 34,864 41,387 45,126 - 56,927 48,340 38,751 - 42,407 - - - - - - 3,056 2,781 1,590 1,322 1,233 1,310 1,081
営業費用 58 64 3,253 4,421 4,640 6,099 7,234 8,883 - 10,950 13,785 20,965 - 24,354 31,070 23,499 - 24,795 24,484 29,426 - 24,612 23,398 18,548 - 27,856 36,330 37,135 - 41,288 46,466 49,346 - 60,457 51,339 41,037 - 44,457 54,048 60,045 - 40,702 42,662 37,876 3,083 2,909 1,720 1,455 2,674 1,406 1,264
営業利益 - - -2,869 -3,975 -3,911 -4,943 -5,617 -7,238 - -8,951 -10,928 -17,848 - -20,923 -27,256 -19,504 - -20,974 -21,212 -25,129 - -21,287 -19,830 -14,832 - -24,717 -33,022 -34,362 - -38,106 -41,637 -27,072 - -50,923 -45,039 -24,974 - -29,278 -35,179 -39,921 -35,392 -26,229 -18,841 -20,747 -2,667 -2,472 -1,773 -1,142 -2,440 -859 -871
営業利益率 (%) - - - - - - - - - - 3345.28 - - - -221.63
経常(税引前)利益 -58 -75 -13,290 -11,851 -4,254 -6,376 -6,010 -7,674 - -9,184 -10,900 -17,833 - -20,895 -27,228 -19,473 - -20,930 -21,095 -25,016 - -21,157 -19,677 -14,665 - -24,402 -33,220 -35,606 - -39,507 -55,237 -31,967 - -56,849 -51,977 -32,612 - -39,383 -42,652 -47,420 - -49,021 112,831 -29,225 -2,310 -2,414 -1,434 -809 -1,050 -567 -668
経常(税引前)利益率(%) - -3534.57 -1841.45 -1446.63 -410.37 -414.76 -288.8 -334.38 - -324.43 -290.51 -425.97 - -466.91 -561.63 -375.18 - -424.52 -479.06 -451.9 - -530.84 -462.94 -331.96 - -646.68 -882.78 -1025.05 - -1001.01 -908.66 -134.77 - -464.05 -485.72 -168.6 - -198.24 -185.44 -186.65 - -253.56 395.05 -139.72 -555.29 -552.4 2705.66 - - - -169.97
法人税等合計 - 4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 600 -300 - - - - - - -32
実効税率(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0
純利益 -58 -79 -13,290 -11,851 -4,254 -6,376 -6,010 -7,674 -8,361 -9,184 -10,900 -17,833 -17 -20,895 -27,228 -19,473 -17,843 -20,930 -21,095 -25,016 -22,836 -21,157 -19,677 -14,665 -21,427 -24,402 -33,220 -35,606 -39,391 -39,507 -55,237 -31,967 -49,435 -56,849 -51,977 -32,612 -42,088 -39,383 -42,652 -47,420 -42,960 -49,021 112,281 -28,965 -3,603 -2,414 -3,378 -734 -1,090 -609 -653
純利益率(%) - 6373.58 - - - -166.16
一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 12.83 -3.13 -0.37 -0.24 -0.32 -0.06 -0.09 -0.05 -0.06
希薄化後一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 12.39 -3.13 -0.37 -0.24 -0.32 -0.06 -0.09 -0.05 -0.06
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -1,009 -2,260 - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -